APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 2月 2025 16:05:00 条件 Nasdaq GlobeNewswire

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

27 1月 2025 16:00:00 条件 Nasdaq GlobeNewswire

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

13 1月 2025 09:00:00 条件 Nasdaq GlobeNewswire

Apellis Announces Keli Walbert to Join the Board of Directors

10 1月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 1月 2025 16:05:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 12月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

27 11月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

12 11月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

05 11月 2024 07:05:00 条件 Nasdaq GlobeNewswire

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

26 10月 2024 14:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

22 10月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

16 10月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 10月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

25 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

20 9月 2024 05:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 9月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

29 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

08 8月 2024 07:00:01 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 8月 2024 16:05:01 条件 Nasdaq GlobeNewswire